Summary & Overview
HCPCS Q4222: Progenamatrix, Biologic Matrix per Square Centimeter
HCPCS Level II code Q4222 denotes Progenamatrix billed per square centimeter as an add-on code reported in addition to a primary procedure. This code matters nationally because biologic wound matrices are increasingly used in advanced wound care and reconstructive procedures; clear billing guidance affects reimbursement, coding consistency, and clinical documentation across payers. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what Q4222 represents clinically and operationally, how it fits into service lines involving advanced wound management, and what typical sites of service are for billing this product. The publication summarizes national benchmarking context, common payer coverage themes, and recent policy updates that influence add-on product coding and coverage determinations. It also outlines expected documentation elements and where providers typically report Q4222 on the claim. This summary equips coding managers, reimbursement analysts, and clinical leaders with a concise reference to align billing practice with payer policies and to anticipate areas requiring prior authorization or detailed documentation for biologic matrix products.
Billing Code Overview
HCPCS Level II code Q4222 describes Progenamatrix, billed per square centimeter as an add-on, list separately in addition to primary procedure. This code is used for billing a biologic wound matrix product applied to a wound bed and is reported in addition to the primary surgical or wound care procedure when the product is used.
-
Service type: Biologic matrix graft application
-
Typical site of service: Wound care clinics, outpatient surgical centers, hospital outpatient departments, and other settings where surgical or advanced wound procedures are performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with a full-thickness or complex partial-thickness wound (for example, a chronic non-healing diabetic foot ulcer or a deep traumatic skin loss) is evaluated in an outpatient wound clinic or ambulatory surgical center. After debridement and wound bed preparation, the treating clinician elects to apply a biological skin substitute product billed as Q4222 (Progenamatrix) to augment healing. The procedure is performed by a wound care specialist, plastic surgeon, or podiatrist. The workflow includes pre-procedure evaluation and wound measurement, sharp or surgical debridement, hemostasis, placement and securement of the Progenamatrix graft over the prepared wound per square centimeter, and application of a dressing. The service is billed in addition to the primary operative or debridement procedure using Q4222 as an add-on code with documentation of product area (cm2), medical necessity, and any applicable modifiers for circumstance (for example, modifier 22 for unusual procedural services or 59-like modifiers from the provided list when applicable). Typical sites of service are outpatient wound care centers, ambulatory surgical centers, and hospital outpatient departments. Common patient presentation scenarios include chronic diabetic ulcers failing conservative therapy, large traumatic soft tissue defects requiring biologic matrix to support granulation, or post-excisional defects after removal of infected tissue where enhanced biologic scaffold is needed to promote healing.
Coding Specifications
| Modifier | Description | When to Use |
|---|